Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique

Cornea

Volumn 30, Issue 2, 2011, Pages 215-218

  Hashemian, Mohammad Naser ^a   Zare, Mohammad Ali ^a   Rahimi, Firoozeh ^a   Mohammadpour, Mehrdad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anti VEGF; Avastin; bevacizumab; cornea; deep anterior lamellar keratoplasty; vascularization

Indexed keywords

BETAMETHASONE; BEVACIZUMAB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORNEA NEOVASCULARIZATION; CORNEA STROMA; DEEP LAMELLAR ENDOTHELIAL KERATOPLASTY; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REDUCTION; DRUG INJECTION VOLUME; HUMAN; KERATOPLASTY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; TECHNIQUE; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; CORNEAL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAOCULAR; MALE; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 78651364055     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181e291a6     Document Type: Article

References (23)

1. Inoue K, Amano S, Oshika T, et al. Risk factors for corneal graft failure and rejection in penetrating keratoplasty. Acta Ophthalmol Scand. 2001; 79:251-255. (Pubitemid 32577308)
2. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
3. Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc. 2007;79:389-394.
4. Dastjerdi MH, Al-Arfaj KM, Nallasammy N, et al. Topical bevacizumab in the treatment of corneal neovascularization. Arch Ophthalmol. 2009; 127:381-389.
5. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
6. Park HY, Kim SJ, Lee HB, et al. Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea. 2008;27:1151-1155.
7. Mackenzie, SE, Tucker WR, Poole ERG. Bevacizumab (Avastin) for corneal neovascularization-corneal light shield soaked application. Cornea. 2009;28:246-247.
8. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
9. Conn H, Berman M, Kenyon K, et al. Stromal vascularization prevents corneal ulceration. Invest Ophthalmol Vis Sci. 1980;19:362-370.
10. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization: Pathogenesis and inhibition. Cornea. 1987;6:250-257.
11. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
12. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611-613.
13. Liesegang TJ. Epidemiology of ocular herpes simplex: Natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107: 1160-1165.
14. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. BullWorld Health Organ. 2004;82:844-851.
15. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37: 2485-2494.
16. Maguire MG, Stark WJ, Gottsch JD, et al. Collaborative Corneal Transplantation Studies Research Group. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology. 1994;101:1536-1547.
17. Williams KA, Roder D, Esterman A, et al. Factors predictive of corneal graft survival: Report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99:403-414.
18. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
19. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
20. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
21. Yoeruek E, Spitzer MS, Wallenfels-Thilo B, et al. Safety Profile of Bevacizumab on Cultured Human Corneal Cells. Lauderdale, FL: ARVO; 2007.
22. Youn Oh J, Kim MK, Shin MS. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res. 2009;34:85-91.
23. Gerten G. Bevacizumab (Avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea. 2008;27: 1195-1199.